Returns Chart

Key Stats

Customize
Expense Ratio Total Assets Under Management Dividend Yield Turnover Ratio
0.65% 17.55B 0.00% 41.70%
1 Year Fund Level Flows 1 Year Total Returns (Daily) Annualized All Time Total Returns (Daily) Max Drawdown (All)
151.45M 41.76% Upgrade Upgrade

Basic Info

Investment Strategy
The investment seeks long-term capital appreciation. The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies. It is non-diversified.
General
Security Type Mutual Fund
Oldest Share Symbol PRHSX
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name T. Rowe Price
Prospectus Benchmark Index
S&P 500 TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Ziad Bakri 5.00 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 18
151.45M
-4.178B Category Low
8.066B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of March 31, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of April 09, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
31.94%
12.98%
-10.28%
28.09%
1.35%
29.25%
30.27%
0.30%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
8.64%
32.58%
6.22%
-10.08%
24.38%
7.64%
28.22%
21.40%
2.30%
20.66%
3.23%
-11.50%
15.75%
0.73%
32.33%
14.71%
-0.78%
25.42%
7.21%
-3.33%
23.36%
5.55%
21.97%
18.24%
3.43%
28.57%
12.71%
-8.94%
19.66%
1.21%
22.98%
12.67%
0.11%
As of April 09, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-9-21) 0.00%
30-Day SEC Yield (4-1-21) Upgrade
7-Day SEC Yield (4-9-21) Upgrade
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 25.08
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of December 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of December 31, 2020

Asset Allocation

As of December 31, 2020.
Type % Net % Long % Short
Cash 0.04% Upgrade Upgrade
Stock 99.29% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.12% Upgrade Upgrade
Other 0.56% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
UnitedHealth Group Inc 6.37% 376.80 0.13%
Thermo Fisher Scientific Inc 4.05% 476.75 -0.44%
Intuitive Surgical Inc 3.94% 779.47 -0.64%
Merck & Co Inc 3.07% 76.21 -0.13%
Eli Lilly and Co 2.91% 181.77 -1.47%
Danaher Corp 2.91% 234.92 1.10%
Vertex Pharmaceuticals Inc 2.73% 213.60 0.12%
Stryker Corp 2.61% 251.72 -0.63%
Becton, Dickinson and Co 1.98% 247.36 -0.23%
Humana Inc 1.97% 413.51 -1.01%

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee Upgrade
Administration Fee --
Performance Fee --
Switching Fee --
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment Upgrade
Minimum Subsequent Investment Upgrade

Basic Info

Investment Strategy
The investment seeks long-term capital appreciation. The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies. It is non-diversified.
General
Security Type Mutual Fund
Oldest Share Symbol PRHSX
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name T. Rowe Price
Prospectus Benchmark Index
S&P 500 TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Ziad Bakri 5.00 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (4-9-21) 0.00%
30-Day SEC Yield (4-1-21) Upgrade
7-Day SEC Yield (4-9-21) Upgrade
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 25.08
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of December 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of December 31, 2020

Fund Details

Key Dates
Inception Date 3/23/2016
Last Annual Report Date 12/31/2020
Last Prospectus Date 5/1/2020
Share Classes
PRHSX No Load
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No